Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. The metric has seen a significant loss of -50.13% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -45.97%. Over the past 30 days, the price of DNA has leaped by -26.07%. And in the last five days, it has fallen by -11.28%.
In terms of market performance, Ginkgo Bioworks Holdings Inc had a somewhat inconsistent run in. The highest value for the stock in the past year was $2.55 on 07/19/23, while the lowest value was $0.85 on 04/22/24.
52-week price history of DNA Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Ginkgo Bioworks Holdings Inc’s current trading price is -66.88% away from its 52-week high, while its distance from the 52-week low is -0.85%. The stock’s price range for this period has been between $0.85 and $2.55. The Healthcare sector company’s shares saw a trading volume of about 51.94 million for the day, which was higher than the average daily volume of 23.35 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Ginkgo Bioworks Holdings Inc (DNA) has experienced a quarterly decline of -31.48% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.71B and boasts a workforce of 1218 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.3035, with a change in price of -0.5500. Similarly, Ginkgo Bioworks Holdings Inc recorded 23,413,203 in trading volume during the last 100 days, posting a change of -39.57%.
DNA’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for DNA stands at 0.22. Similarly, the long-term debt-to-equity ratio is also 0.20.
DNA Stock Stochastic Average
As of today, the raw stochastic average of Ginkgo Bioworks Holdings Inc over the past 50 days is 3.75%. This is a decrease compared to the raw stochastic average of the last 20 days, which was recorded at 7.69%. Additionally, the Stochastic %K and %D values for the company were 11.09% and 10.66%, respectively, over the past 20 days.
